- Home
- IPSC vs BRNS Comparison
IPSC vs BRNS Comparison
Compare IPSC & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPSC
- BRNS
- Stock Information
- Founded
- IPSC 2019
- BRNS 2016
- Country
- IPSC United States
- BRNS United Kingdom
- Employees
- IPSC N/A
- BRNS N/A
- Industry
- IPSC Medicinal Chemicals and Botanical Products
- BRNS Biotechnology: Pharmaceutical Preparations
- Sector
- IPSC Health Care
- BRNS Health Care
- Exchange
- IPSC Nasdaq
- BRNS Nasdaq
- Market Cap
- IPSC 48.2M
- BRNS 38.7M
- IPO Year
- IPSC 2021
- BRNS 2021
- Fundamental
- Price
- IPSC $0.57
- BRNS $1.09
- Analyst Decision
- IPSC Strong Buy
- BRNS Strong Buy
- Analyst Count
- IPSC 5
- BRNS 2
- Target Price
- IPSC $3.33
- BRNS $3.00
- AVG Volume (30 Days)
- IPSC 725.1K
- BRNS 49.3K
- Earning Date
- IPSC 05-15-2025
- BRNS 05-07-2025
- Dividend Yield
- IPSC N/A
- BRNS N/A
- EPS Growth
- IPSC N/A
- BRNS N/A
- EPS
- IPSC N/A
- BRNS N/A
- Revenue
- IPSC $114,898,000.00
- BRNS $14,969,000.00
- Revenue This Year
- IPSC $833.10
- BRNS N/A
- Revenue Next Year
- IPSC N/A
- BRNS N/A
- P/E Ratio
- IPSC N/A
- BRNS N/A
- Revenue Growth
- IPSC 8286.72
- BRNS 4381.74
- 52 Week Low
- IPSC $0.34
- BRNS $0.64
- 52 Week High
- IPSC $3.46
- BRNS $2.14
- Technical
- Relative Strength Index (RSI)
- IPSC 55.48
- BRNS 59.44
- Support Level
- IPSC $0.53
- BRNS $0.65
- Resistance Level
- IPSC $0.59
- BRNS $1.11
- Average True Range (ATR)
- IPSC 0.04
- BRNS 0.12
- MACD
- IPSC -0.00
- BRNS 0.02
- Stochastic Oscillator
- IPSC 59.44
- BRNS 91.23
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.